Tag Archives: Epilepsy Foundation

GWPH Phase 3 Results

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, Sept. 26, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex.


Top